Zhang Jing-Liao, Zhu Xiao-Fan
Diagnosis and Treatment Center of Pediatric Blood Diseases, Institute of Hematology and Blood Disease Hospital, Pecking Union Medical College, Chinese Academy of Medical Sciences, Tianjin 300021,China.
Zhongguo Dang Dai Er Ke Za Zhi. 2015 Jan;17(1):100-6.
The defectiveness of bone marrow mesenchymal stem cells (BM-MSCs) in acquired aplastic anemia (AA) has been a frequent research topic in recent years. This review summarizes the defectiveness of BM-MSCs which is responsible for the mechanism of acquired AA and the prospective application of BM-MSCs in the treatment of acquired AA. An increasingly number of laboratory statistics has demonstrated that the defectiveness of BM-MSCs is more likely to play an important role in the pathogenesis of AA, namely, the apparently different biological characteristics and gene expression profiles, the decreased ability of supporting hematopoiesis as well as self-renewal and differentiation, and the exhaustion of regulating immune response of hematopoietic environment. Those abnormalities continuously prompt AA to become irreversible bone marrow failure along with the imbalanced immunity. With deepening research on MSCs, infusion of MSCs for the primary purpose of recovering hematopoietic microenvironment may become a new approach for the treatment of AA.
近年来,骨髓间充质干细胞(BM-MSCs)在获得性再生障碍性贫血(AA)中的缺陷一直是热门研究课题。本综述总结了BM-MSCs的缺陷,其与获得性AA的发病机制有关,以及BM-MSCs在获得性AA治疗中的潜在应用。越来越多的实验室统计数据表明,BM-MSCs的缺陷更有可能在AA的发病机制中发挥重要作用,即明显不同的生物学特性和基因表达谱、支持造血以及自我更新和分化的能力下降,以及调节造血环境免疫反应的功能耗竭。随着免疫失衡,这些异常不断促使AA发展为不可逆的骨髓衰竭。随着对间充质干细胞研究的深入,以恢复造血微环境为主要目的的间充质干细胞输注可能成为治疗AA的新方法。